Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Risa Kagan

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Bone|March 3, 2007
A cross-sectional study of bone turnover markers in healthy premenopausal womenAnne E de Papp, Henry G Bone, Michael P Caulfield, et al.
Obstetrics and Gynecology|June 12, 2018
A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled TrialRogerio A Lobo, David F Archer, Risa Kagan, et al.
Climacteric : the Journal of the International Menopause Society|August 7, 2025
Major adverse cardiovascular events risk in menopausal women treated with oral estradiol/micronized progesterone versus conjugated estrogens/medroxyprogesterone: a claims data analysis in the USAJohn C Stevenson, Rodney Baber, Risa Kagan, et al.
Menopause (New York, N.Y.)|July 10, 2004
Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosisMarjorie Luckey, Risa Kagan, Susan Greenspan, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|November 6, 2019
Proceedings of the 2019 Santa Fe Bone Symposium: New Concepts in the Care of Osteoporosis and Rare Bone DiseasesE Michael Lewiecki, John P Bilezikian, Risa Kagan, et al.
The Journal of Clinical Endocrinology and Metabolism|April 26, 2006
Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two yearsSydney Bonnick, Kenneth G Saag, Douglas P Kiel, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|December 28, 2004
Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind studyClifford J Rosen, Marc C Hochberg, Sydney L Bonnick, et al.
Menopause (New York, N.Y.)|May 16, 2018
Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual HealthStephanie S Faubion, Lisa C Larkin, Cynthia A Stuenkel, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 20, 2016
Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for OsteoporosisSteven R Cummings, Felicia Cosman, E Michael Lewiecki, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Bone|March 3, 2007
A cross-sectional study of bone turnover markers in healthy premenopausal womenAnne E de Papp, Henry G Bone, Michael P Caulfield, et al.
Obstetrics and Gynecology|June 12, 2018
A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled TrialRogerio A Lobo, David F Archer, Risa Kagan, et al.
Climacteric : the Journal of the International Menopause Society|August 7, 2025
Major adverse cardiovascular events risk in menopausal women treated with oral estradiol/micronized progesterone versus conjugated estrogens/medroxyprogesterone: a claims data analysis in the USAJohn C Stevenson, Rodney Baber, Risa Kagan, et al.
Menopause (New York, N.Y.)|July 10, 2004
Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosisMarjorie Luckey, Risa Kagan, Susan Greenspan, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|November 6, 2019
Proceedings of the 2019 Santa Fe Bone Symposium: New Concepts in the Care of Osteoporosis and Rare Bone DiseasesE Michael Lewiecki, John P Bilezikian, Risa Kagan, et al.
The Journal of Clinical Endocrinology and Metabolism|April 26, 2006
Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two yearsSydney Bonnick, Kenneth G Saag, Douglas P Kiel, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|December 28, 2004
Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind studyClifford J Rosen, Marc C Hochberg, Sydney L Bonnick, et al.
Menopause (New York, N.Y.)|May 16, 2018
Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual HealthStephanie S Faubion, Lisa C Larkin, Cynthia A Stuenkel, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 20, 2016
Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for OsteoporosisSteven R Cummings, Felicia Cosman, E Michael Lewiecki, et al.
Pageof 4